Galvanize Therapeutics raises $130 million Series D led by HealthQuest Capital
The financing will support commercial expansion of the Aliya platform, clinical evidence and new pulsed electric field devices.
Galvanize Therapeutics announced the close of a $130 million Series D on 16 November. HealthQuest Capital led the oversubscribed round, with Olympus Innovation Ventures and Braidwell LP joining as new investors.
Existing backers also participated, including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates Inc.
The Redwood City company will use the funding to expand its Aliya business, generate clinical evidence and develop additional pulsed electric field products. Its pipeline includes RheOx, an investigational therapy for chronic bronchitis. HealthQuest’s Garheng Kong will join the board.
Use of funds
Aliya commercial expansion
Clinical evidence generation
AdvanceRheOx
NextgenerationPEFplatforms